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We have implemented an unbiased cell morphology–based screen to identify small-molecule modulators of cellular
processes using the Cytometrix (TM) automated imaging and analysis system. This assay format provides unbiased
analysis of morphological effects induced by small molecules by capturing phenotypic readouts of most known classes
of pharmacological agents and has the potential to read out pathways for which little is known. Four human-cancer cell
lines and one noncancerous primary cell type were treated with 107 small molecules comprising four different protein
kinase–inhibitor scaffolds. Cellular phenotypes induced by each compound were quantified by multivariate statistical
analysis of the morphology, staining intensity, and spatial attributes of the cellular nuclei, microtubules, and Golgi
compartments. Principal component analysis was used to identify inhibitors of cellular components not targeted by
known protein kinase inhibitors. Here we focus on a hydroxyl-substituted analog (hydroxy-PP) of the known Src-family
kinase inhibitor PP2 because it induced cell-specific morphological features distinct from all known kinase inhibitors in
the collection. We used affinity purification to identify a target of hydroxy-PP, carbonyl reductase 1 (CBR1), a short-
chain dehydrogenase-reductase. We solved the X-ray crystal structure of the CBR1/hydroxy-PP complex to 1.24 A ˚
resolution. Structure-based design of more potent and selective CBR1 inhibitors provided probes for analyzing the
biological function of CBR1 in A549 cells. These studies revealed a previously unknown function for CBR1 in serum-
withdrawal-induced apoptosis. Further studies indicate CBR1 inhibitors may enhance the effectiveness of anticancer
anthracyclines. Morphology-based screening of diverse cancer cell types has provided a method for discovering potent
new small-molecule probes for cell biological studies and anticancer drug candidates.
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PLoS Biol 3(5): e128.
Introduction
Many current drugs were originally discovered through
observation of unexpected biological activities (e.g., penicil-
lin, benzodiazepines, sildenaﬁl [Viagra]). Broad screens for
biological function have the advantage of identifying the best
‘‘lock’’ for each new ‘‘key’’ produced by chemical variation. In
contrast, the search for drug-like hits by high-throughput
approaches is dominated by in vitro single-enzyme activity–
based screens and single-readout cell-based assays. These
approaches measure very limited regions of biological space
and do not reveal potent effects on pathways not being
measured directly. In order to systematize the understanding
of the full activity of new small molecules, we quantiﬁed dose-
dependent morphological changes induced in ﬁve cell types,
thereby identifying ‘‘hit’’ compounds with unique activities.
The assay is based on the principle that many cellular
targets are involved in the control of cellular morphology,
DNA content and location, and morphology of the Golgi
apparatus ([1,2,3]; C. L. Adams, D. A. Coleman, G. Cong, A. M.
Crompton, K. A. Elias, et al., unpublished data). Cell-type-
speciﬁc components are known to utilize distinct pathways
and cellular programs to control fundamental processes
affecting the features of the organelles and the overall
cellular morphology. Five cell types (lung adenocarcinoma,
ovarian cancer, a neuronal glioma, a prostate cancer, and
endothelial cells) were included in the morphological screen.
The approach has been validated by analysis of known
pharmacologically active compounds from ten different
mechanism of action classes (actin inhibitors, calmodulin
antagonists, endoplasmic reticulum Ca
2þ ATPase inhibitors,
geranylgeranyl transferase-1 inhibitors, G-protein-coupled
receptor activators, protein kinase C activators, topoisomer-
ase II inhibitors, tubulin destabilizers, tubulin stabilizers, and
kinase inhibitors). In every case, a high percentage of the
compounds were accurately classiﬁed into the ten different
mechanism of action groups using the Cytometrix (TM)
s y s t e m( C .L .A d a m s ,D .A .C o l e m a n ,G .C o n g ,A .M .
Crompton, K. A. Elias, et al., unpublished data).
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chemical scaffolds known to inhibit protein kinases with
varying selectivity and potency were selected for the Cytome-
trix screen. In this report, we focus on a hydroxyl-substituted
analog, 3-(1-tert-butyl-4-amino-1H-pyrazolo[3,4-d]pyrimidin-
3-yl)phenol (hydroxy-PP), of the known Src-family protein
kinase inhibitor 1-tert-butyl-3-(4-chlorophenyl)-1H-pyrazolo
[3,4-d]pyrimidin-4-amine (PP2), because it exhibited a cell
response proﬁle distinct from the known kinase inhibitors
including the closely related compound PP2. Although the
compound collection was dominated by kinase-inhibitor
scaffolds, we identiﬁed a nonkinase target of hydroxy-PP,
carbonyl reductase 1 (CBR1), an NADPH-dependent reduc-
tase.Hydroxy-PPandanalogschosenbystructure-baseddesign
wereusedtosearchbothforsignalingpathwaysinwhichCBR1
may be involved and for potential therapeutic uses of CBR1
inhibitors.
Results
Selection of Chemical Library
A collection of 107 compounds containing known protein
kinase inhibitors and close structural analogs were screened
in the Cytometrix assay for unique phenotypic proﬁles
suggestive of potent inhibition of cellular targets not affected
by known protein kinase inhibitors (Figure 1A). The well-
characterized protein kinase inhibitors (K252a [4],
SKB203580 [5], VK-1911 [6], and PP2 [7]) served as positive
controls and ‘‘landmarks’’ for the phenotypes likely to be
induced by the less-characterized compounds in the collec-
tion (Figure S1 contains a complete list of all compounds
tested). An advantage of screening compounds closely related
to each other is the availability of a wealth of structure–
activity relationships in the initial screen that provide a guide
to follow-up studies aimed at improving afﬁnity and target
selectivity in a second round of chemical synthesis.
Phenotypic Profiling Using Microscopy and Automated
Image Analysis
Cellular and organelle morphology changes were measured
from segmented images of cells stained with DNA and
microtubule markers using algorithms that identify cell and
nuclear boundaries (C. L. Adams, D. A. Coleman, G. Cong, A.
M. Crompton, K. A. Elias, et al., unpublished data). Combin-
ing segmentation and intensity distribution algorithms allows
acquisition of multiple shape-, texture-, and intensity-related
features for each image collected. For each object identiﬁed
by the segmentation algorithms, collected attributes include
object location, area, perimeter, and axis ratio, as well as
pixel-intensity sum, mean, variance, and kurtosis (the degree
of peakedness of a distribution).
Cells undergo major morphological changes in the course
of cell-cycle progression [8]. To separate these changes from
ones induced by compound treatment, algorithms were used
to classify cells by their cell-cycle status based on the DNA
content, morphology, and condensation status. The multiple
attributes of individual cells are summarized by a set of
statistics that describe distributions of these attributes in a
population of cells. These statistics are termed ‘‘phenotypic
attributes.’’ The attributes used to characterize the screening
compounds are listed in Table S1. These attributes were
chosen for their biological information content and their low
correlation with each other (C. L. Adams, D. A. Coleman, G.
Cong, A. M. Crompton, K. A. Elias, et al., unpublished data).
Phenotypic Landmarks: Compounds with Known
Mechanisms of Action
Principle component analysis (PCA) was used to reduce the
dimensionality in the dataset to allow visual investigation of
patterns in the multivariate signature. This transformation
converts a number of correlated variables into a smaller
number of uncorrelated variables, or principal components,
in such a way that the ﬁrst few components account for as
much of the variability in the dataset as possible [9].
Importantly, component values are not physical constants
but are dependent on the relative ‘‘spread’’ of the attributes
derived from all the images in the dataset.
The plot of principle components 1, 2, and 3 derived from
image analysis of the effects of 107 compounds (at eight
different concentrations ranging from 6 nM to 40 lM) on ﬁve
cell types is shown in a scatter plot (Figure 1B). In this analysis
the morphological features making up the individual compo-
nents are given in Table S2. We observed four distinct
‘‘phenotypes’’ induced by various members of the compound
collection. At the lowest concentrations tested, compounds
cluster with the dimethyl sulfoxide (DMSO) and untreated
controls. This region, approximately in the center of the PCA
plot, constitutes the attribute proﬁle characteristic of no
effect on cellular morphology.
The remaining three phenotypic categories are character-
ized by compounds that exhibit distinct ‘‘trajectories’’ such
that at increasing concentrations different attributes are
enhanced, indicative of a measurable dose-dependent phe-
notype. The cells treated with the microtubule-polymerizing
natural product paclitaxel exhibit a pronounced and highly
reproducible trajectory and constitute the second phenotype
observed. Each of the ﬁve cell types exhibited reproducible
changes in attributes associated with tubulin staining and
cell-cycle status, as expected for a microtubule-polymerizing
agent [10].
A third characteristic phenotype is exempliﬁed by the
potent general kinase inhibitor K252a. The bisindolocarba-
zole K252a is a potent inhibitor of over 50 known kinases
from diverse families [4]. This compound induced dose-
dependent morphological changes in A549, DU145, HUVEC,
and SF268 cells but not SKOV3 cells (data not shown). We
attribute the majority of the observed changes in morpho-
logical attributes to the kinase-inhibitory activity of K252a,
rather than to any off-target effects, because K252a analogs
(compounds 103–107 in Figure S1) that were lacking the
ability to inhibit protein kinases [11] clustered with the ‘‘no
phenotype’’ controls. That the K252a-induced phenotype was
caused by inhibition of cellular kinases is consistent with the
clustering of the K252a trajectory with trajectories of other
known kinase inhibitors (PP2 and SKB203580). Although the
kinase targets of each of these compounds are not fully
characterized, the fact that the compounds share a similar
proﬁle in the Cytometrix assay suggests that they have
overlapping targets (i.e., PP2 and SKB203580 inhibit p38),
as has been reported elsewhere [12].
The fourth phenotype was produced by a structurally
related pyrazolopyrimidine in the collection, hydroxy-PP
(compound 87 in Figure S1) (Figure 1C). The cellular
attributes characteristic of this compound are distinct from
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Cell Morphology–Based Genetic Screenthe phenotypes induced by kinase inhibitors and the micro-
tubule depolymerization inhibitors (Figure 1B). In order to
best distinguish the cellular attributes unique to hydroxy-PP, a
close structural analog, PP2, was used as a reference. Hydroxy-
PP bears a meta-OH substituent, whereas PP2 has a para-Cl
substituent on the C-3 phenyl ring [7]. Other close analogs of
PP2 (Figure 1C), such as 1-tert-butyl-3-phenyl-1H-pyrazolo
[3,4-d]pyrimidin-4-amine (PP; compound 1 in Figure S1), that
lack any substituent on the C-3 phenyl ring showed a
phenotypic proﬁle comparable to PP2. (For this reason we
used PP2 and PP interchangeably.) These structure–activity
relationships suggested that the meta-OH substituent was
critical for interaction with a protein target that is not
affected by PP2.
The cellular effects induced by hydroxy-PP and PP2 were
further examined by analysis of the quantitative attribute
changes at approximately the EC50 value for each compound
(as judged by distance in PCA space from the DMSO controls;
Figure 1B). Figure 1D shows that the two compounds
hydroxy-PP and PP2 exhibit indistinguishable effects on
DU145, SF268, and SKOV3 cells. However, the two com-
pounds exhibit cellular activities that are distinct from each
other in A549 lung adenocarcinoma and HUVEC cells.
Examples of the cell images that were analyzed by the
Cytometrix algorithms and are directly relevant to the
morphological differences induced by PP2 or hydroxy-PP
are shown in Figure 1E. The PP2-treated A549 cells appear
more elongated and slightly more condensed than the
hydroxy-PP2-treated cells, leading to the quantitative differ-
ences plotted in Figure 1D. That only two of ﬁve cell types
exhibited differential responses to two closely related
molecules highlights the importance of including cells
representing a diversity of tissue sources and genetic makeup
in order to explore a wide range of possible small-molecule
targets (C. L. Adams, D. A. Coleman, G. Cong, A. M.
Crompton, K. A. Elias, et al., unpublished data). Attempts to
directly assign the molecular target or targets responsible for
the hydroxy-PP-induced changes to morphological features
using compounds previously proﬁled using the Cytometrixe
system were not possible because the subtle differences
observed were not strongly characteristic of any compounds
previously proﬁled (unpublished data).
Hydroxy-PP Molecular Target Identification
With no cell pathway–speciﬁc information about the target
or targets of hydroxy-PP, we relied on the differential
sensitivity of A549 cells to hydroxy-PP and the kinase
inhibitors PP2 and PP. Our hypothesis was that hydroxy-PP
and PP share targets in common based on the similarity of
their Cytometrix proﬁles in DU145, SF268, and SKOV3 cells
(Figure 1D). A corollary of this hypothesis is that hydroxy-PP
targets one or more proteins in A549 and HUVEC cells that
are not targeted by PP, thus leading to differential morpho-
logical attributes in A549 and HUVEC cells (Figure 1D).
As a test of the ﬁrst hypothesis, we focused on identi-
ﬁcation of enzymes that are potently inhibited (IC50 , 1 lM)
by PP and hydroxy-PP. Based on the known protein kinase–
inhibitory properties of PP2 and its structural homologs,
including PP [7,13], we predicted that hydroxy-PP was also a
protein kinase inhibitor. We tested hydroxy-PP against four
divergent protein kinase targets: the tyrosine kinase Fyn,
[7,13], p38-a, protein kinase A, and protein kinase B (Table
S3). The additional -OH moiety of hydroxy-PP, did not
diminish kinase-inhibitory activity toward Fyn, the best
known target of PP2; instead, it enhanced it such that
hydroxy-PP exhibited a 5-nM IC50 for Fyn inhibition. Similar
to what occurred with PP, hydroxy-PP did not exhibit potent
inhibition of any of the three other kinases tested (Table S3).
To test the corollary hypothesis, we opted for a direct
approach utilizing the differential sensitivity of A549 cells,
rather than attempting to identify the unique targets of
hydroxy-PP among the protein kinases, for which the differ-
ential effects are likely to be small due to the highly conserved
ATP-binding pockets of protein kinases. Very few biochem-
ical or genetic methods are available for identiﬁcation of the
molecular targets of small molecules in cells [14]. The most
commonly used method is afﬁnity puriﬁcation by immobili-
zation of the small molecule on a solid phase matrix. This
technique requires both a high-afﬁnity small molecule that
allows stringent washing of weakly bound targets and a
relatively abundant target to allow for mass spectrometry
(MS)–based sequence identiﬁcation. These two properties are
not often found in early ‘‘hits’’ from random screening efforts
like ours. Nonetheless, we decided to attempt afﬁnity
puriﬁcation of the targets of hydroxy-PP using hydroxy-PP
beads with PP beads as a negative control.
To ensure that attachment of a linker to hydroxy-PP did
not destroy the target-binding properties, we synthesized a
linker-containing analog of hydroxy-PP, hydroxy-PP-L, and a
similar linker analog of PP, PP-L (Figure 1C). These N-1
analogs of hydroxy-PP and PP were proﬁled using the
Cytometrix system and were found to have the same
trajectories as their parent compounds, albeit with approx-
Figure 1. Cell Morphology–Based Screen for Biologically Active Small Molecules
(A) Steps in the drug-screening process. Five human cell types, including one primary and four cancer cell lines, were treated for 24 h with the
screening library that included compounds of known function and related analogs. The Cytometrix (TM) data analysis package was used to
analyze microscopy data for each treatment condition.
(B) PCA plot of the phenotypic attributes. Colored spheres represent a single compound at one concentration (ranging from 6 nM to 40 lMb y
3-fold increases); lines connecting the spheres indicate a single compound’s effects over a range of concentrations. Spheres are colored as
follows: known protein kinase inhibitors (blue), paclitaxil (green), and novel compounds structurally related to the protein kinase inhibitors
(red). The PCA provides aggregate variables termed ‘‘components’’ made up of multiple independent variables, each with a ‘‘loading factor.’’
These values are provided in Table S2. Structures of each compound are given in Figure S1.
(C) Structures of the known kinase inhibitors PP and PP2 (blue), as well as the novel ‘‘hit compound’’ hydroxy-PP (red), are shown. Linker analogs
of PP (PP-L) and hydroxy-PP (hydroxy-PP-L) that were used to ascertain the functional tolerance of replacing the t-butyl substituent at N-1 of
the ‘‘hit compound’’ hydroxy-PP are shown.
(D) Morphological attribute tabulation for cells treated with 129.4 lM PP2 (blue lines) or 0.4 lM hydroxy-PP (red lines) in each of ﬁve cell types.
Data for the x-axis is grouped by the probe used (a-tubulin antibody, Hoechst dye, and lectin stain). Each of 14 attributes contributing to the
magnitude of the response (y-axis) is shown as a red-ﬁlled square.
(E) Visual morphology of A549 cells treated with hydroxy-PP or PP2. Hoechst dye or a-tubulin antibody was used to stain cells. The PP2-treated
cells are more elongated and have more a condensed nuclear structure as compared with hydroxy-PP-treated cells.
DOI: 10.1371/journal.pbio.0030128.g001
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loss in potency is not uncommon for linker-containing
analogs [16], and importantly demonstrates that the tert-butyl
s u b s t i t u e n ta tN - 1i sn o tr e q u i r e df o rt a r g e tb i n d i n g .
Reactigel beads presenting either hydroxy-PP or PP2 were
subsequently synthesized (Figure 2A).
A wide range of buffer conditions were explored to
identify conditions under which proteins speciﬁcally bound
to hydroxy-PP beads but not PP2 beads or underivatized
beads (Figure 2B, lane 3 versus lanes 1 and 2). Eight silver-
stained protein bands at molecular weights of 15–38 kDa
were retained on hydroxy-PP beads under these buffer
conditions. To further distinguish those proteins that were
speciﬁcally targeted by hydroxy-PP, and not by features of
the linker or beads, the lysate was pretreated with DMSO,
PP, or hydroxy-PP, the latter two compounds at 200 lM.
Three bands (B1–B3) were not capable of binding to the
hydroxy-PP beads with hydroxy-PP treatment, suggesting
that these proteins were the targets of hydroxy-PP. Using
matrix-assisted laser desorption/ionization (MALDI) and
electrospray ionization (ESI) MS/MS sequencing, B1–B3 were
each identiﬁed as human CBR1, a member of the short-
chain dehydrogenase/reductase family of NAD(P)(H) oxidor-
eductases (Figure 2C). The presence of three forms of CBR1
with differing electrophoretic mobilities has been previously
observed and is believed to result from autocatalytic
modiﬁcation of a lysine residue [16]. Four of the other ﬁve
protein bands that were not competed off by hydroxy-PP,
but that also bound to the hydroxy-PP afﬁnity matrix, were
identiﬁed as nucleoside diphosphate kinase, nucleoside
diphosphate kinase 2 (nm23) and pyridoxal kinase
Figure 3. IC50 Values against CBR1 and Fyn Kinase Are Tabulated for PP
Derivatives
DOI: 10.1371/journal.pbio.0030128.g003
Figure 2. Affinity Purification and Identification of Human CBR1
(A) Reactigel beads appended with hydroxy-PP or PP (control) were
used for afﬁnity puriﬁcation of hydroxy-PP protein targets.
(B) Hydroxy-PP-binding proteins in A549 cell lysates. Cytosolic
fractions of A549 cell lysate (1.7 mg protein each) were incubated
with the indicated afﬁnity resin, and bound proteins were resolved by
SDS-PAGE (12% acrylamide gel) followed by silver staining. Un-
treated beads and PP-control resin samples (lanes 1 and 2) indicate
little nonspeciﬁc binding. Lanes 3, 4, 5, and 6 were loaded using the
hydroxy-PP resin incubated with cell lysate and the indicated
competitor. Vehicle or competitor compounds (200 lM) were added
to the lysate 30 min before incubation with beads (lanes 4–6). Protein
of bands B1–B3 did not bind hydroxy-PP beads when pretreated with
hydroxy-PP (lane 5).
(C) MS/MS peptide sequencing. Two tryptic peptides from bands B1–
B3 were used to identify human CBR1.
DOI: 10.1371/journal.pbio.0030128.g002
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afﬁnity beads following hydroxy-PP treatment (Figure 2B,
lane 5), we concluded they were recognizing a feature of the
linker used to attach hydroxy-PP to the beads and so were
not pursued.
To initially validate that the oxidoreductase CBR1 was
indeed inhibited by hydroxy-PP, we measured CBR1 catalytic
activity in vitro in the presence of hydroxy-PP or PP
(Figure 3). Hydroxy-PP exhibited potent (IC50 = 788 nM)
inhibition of CBR1-catalyzed NADPH-dependent reduction
of menadione to menadiol [17]. In contrast, PP exhibited no
inhibition of CBR1 activity up to its solubility limit of 200 lM.
This differential inhibition of CBR1 by hydroxy-PP but not
PP validated our initial hypothesis that these two compounds
possess different targets.
To determine how the inhibition of CBR1 by hydroxy-PP
was related to the original Cytometrix screen, the entire
screening collection was re-screened in vitro for inhibition of
CBR1. The only member of the collection that showed
inhibition of CBR1 below an IC50 value of 1 lM was hydroxy-
PP (data not shown). These screening data suggest that the
morphology-based screen provided an efﬁcient measure of
the inhibitory potential of CBR1 inhibition, even though the
screen included no direct measurements designed to read out
CBR1 function. To determine whether the absence of an
observable differential effect of hydroxy-PP, as compared
with PP2, on SKVO3, DU145, and SF268 cells was due to an
absence of CBR1 expression in these cells, we carried out a
protein immunoblot analysis of CBR1 expression levels in
each of the cell types analyzed by Cytometrix. Each of the cell
types expressed CBR1 at approximately equal levels (Figure
S2), suggesting that multiple factors other than expression
level regulate CBR1 activity.
Structural Characterization of Hydroxy-PP–CBR1 Complex
In order to develop a pharmacological agent that specif-
ically inhibits CBR1, we addressed the target speciﬁcity of
hydroxy-PP. In particular, hydroxy-PP’s ability to potently
inhibit the cytoplasmic tyrosine kinase Fyn (IC50 = 5 nM) in
addition to CBR1 (IC50 = 788 nM) makes it a poor tool for
probing CBR1 functions exclusively. We overexpressed
human CBR1 in Escherichia coli and attempted crystallization
of the protein in the presence of hydroxy-PP in an effort to
enhance design of a selective CBR1 inhibitor. Within 2 d at
room temperature, good diffracting crystals of the ortho-
rhombic space group P212121 were obtained by vapor
diffusion from 100 mM sodium-2-(N-ethylmorpholino)etha-
nesulfonate (pH 6.5), 2.0 M ammonium sulfate, and 5% PEG
400. Orthorhombic crystals of CBR1–hydroxy-PP diffracted
to 1.1 A ˚ . The structure was solved by molecular replacement
with the AMoRe program [18] using a modiﬁed porcine
carbonyl reductase [19] model and reﬁned with SHELXL [20]
to 1.24 A ˚ with a crystallographic R-factor of 10.3% and a free
R-factor of 13.4%.
Human CBR1 shows very high structural similarity to
porcine carbonyl reductase, whose sequence is 85% identical
to human CBR1 [21]. Although NADP(H) was not present
during puriﬁcation of the enzyme from E. coli nor added to
the crystallization experiments, one molecule of NADP was
found to be bound in the CBR1–hydroxy-PP structure. The
same occurrence has been reported for the structure of
porcine carbonyl reductase [19]. Hydroxy-PP binds to the
substrate-binding site of CBR1, with the pyrazolopyrimidine
core of hydroxy-PP mainly surrounded by hydrophobic
residues (Trp229, Met141, and Ile140). The phenolic hydroxyl
group of hydroxy-PP, however, points deep into the
substrate-binding pocket and interacts with Tyr139 and
Ser193 of the catalytic triad. The phenolic oxygen is
positioned 2.5 A ˚ from O
g of Tyr139 and 2.5 A ˚ from O
c of
Ser193, thus indicating strong hydrogen bonding. The C4
carbon of the NADP(H) nicotinamide ring is positioned 3.2 A ˚
from the meta-hydroxy carbon. This four-point geometry is
iso-structural to the structures of other short-chain dehydro-
Figure 4. Co-Crystal Structures of CBR1–Hydroxy-PP and Hck–PP1
(A, C, and E) show the binding mode of hydroxy-PP in co-crystals with
CBR1. The inhibitor is oriented with its t-butyl group partially
exposed to solvent and points toward the surface of the protein. The
phenolic moiety of the inhibitor binds deeply within the substrate-
binding pocket and makes close contacts to Ser193 and Tyr139 of the
catalytic triad and the bound cofactor NADP. (B, D, and F) show the
binding mode of the kinase inhibitor PP1 in complex with Hck. PP1
occupies the ATP-binding pocket as an adenosine analog. Although
both protein structures show different folds (A and B), the
morphology of CBR1- and Hck-binding sites are similar, and
inhibitors hydroxy-PP and PP1 bind to these sites with similar shape
complementarity (C and D). Key H-bond interactions between
hydroxy-PP and the Ser193 and Tyr139 of CBR1 are indicated (E).
The exocyclic amine of PP1 in complex with Hck makes essential H-
bonds with the main-chain carbonyl oxygen of Glu339 and the side-
chain oxygen of Thr338 (F). Disruption of this key H-bonding
interaction by derivatization of the exocyclic amine destroys kinase
afﬁnity. The ﬁgure was prepared using the PyMol 2002 graphics
system (DeLano Scientiﬁc, San Carlos, California, United States).
DOI: 10.1371/journal.pbio.0030128.g004
PLoS Biology | www.plosbiology.org May 2005 | Volume 3 | Issue 5 | e128 0769
Cell Morphology–Based Genetic Screengenase substrate complexes (e.g., PDB 2AE2, 1FDS, and 1HZJ)
and suggests a substrate-like binding mode of hydroxy-PP.
Importantly, the structure of CBR1–hydroxy-PP provides a
molecular understanding of the basis for the strong depend-
ence of CBR1 inhibition on the presence of a hydroxyl
moiety, as this functional group serves as a key interaction
determinant with the catalytic machinery of CBR1. The
binding mode of hydroxy-PP in CBR1 also explains the
tolerance of the pyrazolopyrimidine core to derivatization at
N-1, which allowed attachment of hydroxy-PP to solid
support and afﬁnity puriﬁcation of CBR1.
Design and Synthesis of a CBR1-Selective Inhibitor
The availability of the X-ray structures of hydroxy-PP
bound to CBR1 and of 1-tert-butyl-3-p-tolyl-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (PP1) bound to the tyrosine kinase Hck
[22] afforded us the opportunity to compare how two virtually
identical small molecules (PP1 and hydroxy-PP) are able to
bind to two completely structurally and functionally unre-
lated enzyme targets (Figure 4A and 4C versus 4B and 4D).
Strikingly, the two co-crystal structures show grossly isosteric
active site surfaces that are complementary to the two
pyrazolopyrimidines. The geometries of both the pyrazolo-
pyrimidine C-3 phenyl bond and orientation within the
binding clefts are conserved within the two complexes. This
ﬁnding complicates the design of a hydroxy-PP analog that
cannot bind to protein kinases because the two binding clefts
are highly similar in geometry. To design an analog of
hydroxy-PP containing substituents that would disrupt
protein kinase binding, we focused on electronic rather than
steric aspects of the complexes. The exocyclic amine of PP2 is
known to make key H-bond interactions with O
c of Thr338
and O of Glu339 in the linker region of the protein kinase
active site pocket (Figure 4F) [22]. We designed and
synthesized a mono-methyl-substituted version of hydroxy-
PP, 3-(7-isopropyl-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimi-
din-5yl)phenol (hydroxy-PP-Me), predicted to disrupt this key
H-bonding interaction in kinases. Importantly, structural
analysis of the hydroxy-PP–CBR1 co-crystal structure revealed
a small space in the active site capable of tolerating a methyl
substituent at this position (Figure 4E).
Indeed, hydroxy-PP-Me maintained potent inhibition activ-
ity against CBR1 (IC50 = 759 nM) but was an extremely poor
inhibitorof thecytoplasmictyrosinekinaseFyn (IC50.70lM;
see Figure 3). Because hydroxy-PP-Me lacks an H-bond donor
group known to be key for potent protein kinase inhibition,
we anticipate that it is an extremely poor inhibitor of all
cellular protein kinases. A small screen against four protein
kinases (Fyn, p38-a, protein kinase A, and protein kinase B)
(see Table S3) has shown that none are inhibited by hydroxy-
PP-Me. Further in vitro screens against a large panel of
protein kinases will be required to experimentally conﬁrm
this assertion.
CBR1 and Cancer Therapy
The carbonyl reductase CBR1 was ﬁrst isolated from brain
[17] and has been associated with two cellular functions: (1)
detoxiﬁcation of xenobiotics, such as the anthracycline
daunorubicin and (2) metabolism of ketone-containing
cellular messengers, such as prostaglandin E (reviewed in
[23]). Genetic studies that have intended to uncover the in
vivo function of this enzyme have focused on the xenobiotic
detoxiﬁcation activity of the enzyme. CBR1 converts daunor-
ubicin into daunorubicinol, a compound that lacks the anti-
proliferative activity of the parent daunorubicin and is
cardiotoxic. Thus, metabolism of daunorubicin by CBR1 is
thought to be responsible for the severe cardiotoxicity
associated with daunorubicin treatment. In support of this
function, mice heterozygous for a null allele of CBR1 show
reduced sensitivity to anthracycline-induced cardiotoxicity
because reduced CBR1 expression produces lower levels of
doxorubicinol (CBR1 homozygous null mice are nonviable)
[24]. Further support for this model comes from transgenic
mice overexpressing CBR1, which exhibit increased cardio-
toxicity associated with doxorubicin treatment [23]. It has
been suggested [23] that because CBR1-dependent metabo-
lism of the anthracyclines doxorubicin and daunorubicin
reduces their efﬁcacy in tumor-cell killing, a pharmacological
inhibitor of CBR1 should potentiate anthracycline-induced
cancer-cell killing.
To test this hypothesis, we measured the ability of hydroxy-
PP-Me and PP-L to block CBR1-mediated metabolism of
daunorubicin in A549 cells using cell killing as a measure of
the cellular status of daunorubicin metabolism. The potent
kinase inhibitor PP-L, which does not inhibit CBR1, was used
as a negative control to measure general toxicity of
combining daunorubicin with a structurally related but
inactive molecule. A549 cells were treated at a daunorubicin
concentration (440 nM) corresponding to an approximate
IC50 for cell killing as a single agent such that enhanced cell
killing could be scored. Concentrations of PP-L and hydroxy-
PP-Me that exhibited minimal cytotoxicity on A549 cells (8
lM) when used alone were selected for combination with
daunorubicin. Figure 5A shows cell viability results measured
by an alamarBlue reduction assay for A549 cells following
drug treatments. Hydroxy-PP-Me induced a 25% enhance-
ment of daunorubicin-mediated A549-cell killing consistent
with its ability to inhibit CBR1-mediated daunorubicin
metabolism. In contrast, PP-L exhibited no enhancement of
cell killing, further suggesting the need for CBR1 inhibition
to enhance daunorubicin-mediated cell killing. Although the
observed 25% enhancement of daunorubicin-mediated cell
killing is modest, the hydroxy-PP-Me dose dependence
(Figure 5B) of this effect is further evidence that it is CBR1
mediated rather than a general toxic response.
Anti-Apoptotic Effect of Hydroxy-PP-Me Links CBR1
Activity to Serum-Withdrawal-Induced Cell Stress
The embryonic lethal phenotype of CBR1
–/– mice suggests
that the enzyme plays a nonredundant role in cell signaling
during embryogenesis and development. In order to search
for unknown biological roles for CBR1, we utilized the two
structurally related pyrimidine-based inhibitors of CBR1
hydroxy-PP-L and hydroxy-PP-Me. The former inhibits
CBR1 and protein kinases, whereas the latter lacks the
kinase-inhibitory action while maintaining CBR1-inhibitory
activity. PP-L was included as a negative control. Thus, the
three compounds together constitute a probe set for assess-
ment of CBR1 involvement in a variety of cellular processes.
We chose to focus on signals that induce apoptosis in A549
adenocarcinoma cells because this endpoint is important for
many cell-fate decisions, including those relevant to cancer
and inﬂammation [25]. CBR1 has been directly implicated in
redox reactions leading to H2O2 generation, a known
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wide range of cell stresses previously shown to induce
apoptosis: (1) interferon-c þ Fas ligand, (2) H2O2,( 3 )
interleukin-1b, (4) serum withdrawal, or (5) interleukin-1b þ
serum withdrawal. The CBR1 inhibitors hydroxy-PP and
hydroxy-PP-Me showed no enhancement of induction of
apoptosis by any of these conditions (data not shown).
However, both inhibitors were able to block A549-cell
apoptosis induced by serum withdrawal [27]. Propidium
iodide (PI) staining and phase contrast images show that
A549 cells 65 h following serum withdrawal undergo virtually
100% apoptosis whereas cells treated with hydroxy-PP-Me
are almost completely protected against apoptosis, as judged
by the number of PI-negative cells (Figure 5C). The dual
CBR1–protein kinase inhibitor hydroxy-PP-L also protects
A549 cells against serum-withdrawal-induced apoptosis,
although to a lesser extent than hydroxy-PP-Me.
To conﬁrm that inhibition of CBR1 by hydroxy-PP-Me was
Figure 5. CBR1 Inhibitors Enhance Daunorubicin-Mediated A549-Cell Killing, yet Prevent Apoptosis in Serum-Starved Cells
(A) Cell viability as a function of drug treatment. DMSO, PP-L (8 lM), and hydroxy-PP-Me (8 lM) do not have a pronounced effect on cell
viability when used alone. Daunorubicin (DR) alone induces a moderate decrease in cell viability that is accentuated by concomitant treatment
with hydroxy-PP-Me.
(B) Cell viability decreases dose dependently with concomitant daunorubicin (DR) treatment. Daunorubicin treatment induces a moderate
decrease in cell viability when used alone. Hydroxy-PP-Me (1–8 lM) induces a dose-dependent decrease in cell viability with concomitant
daunorubicin treatment.
(C) PI staining of dead cells is appreciably decreased in serum-starved cells treated with CBR1 inhibitors. A high number of cells were PI stained
65 h following serum starvation in both control and PP-L treated conditions (top). Cells treated with the CBR1 inhibitors hydroxy-PP-L or
hydroxy-PP-Me during serum starvation show appreciably less staining (bottom).
(D) Quantiﬁcation of PI-stained cells by ﬂuorescence measurement 65 h following serum starvation. Hydroxy-PP-L and hydroxy-PP-Me induce a
dose-dependent decrease in PI staining; whereas PP-L does not.
DOI: 10.1371/journal.pbio.0030128.g005
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A549 cells, we turned to RNA interference (RNAi) as a means
to validate the role of CBR1 in the process. Three types of 21-
nt RNAi that target human CBR1 were tested for their ability
to knock down CBR1 expression, and their effectiveness was
conﬁrmed with an anti-CBR1 antiserum Western blot (Figure
S3A). The anti-apoptotic effects of these RNAi elements that
target CBR1, as opposed to control RNAi elements that target
an irrelevant target found in A549 cells, further validate that
hydroxy-PP-Me is a potent CBR1 inhibitor in cells and that
CBR1 is involved in serum-withdrawal-induced apoptosis
(Figure S3B).
To begin to determine whether the observed serum-
withdrawal-induced apoptosis in A549 cells is mediated by
the well-characterized p53 pathway, we used RNAi elements
targeting p53 and showed that loss of p53 also protects A549
cells from serum-starvation-induced apoptosis (Figure S3B).
A connection between p53-mediated cell death and another
NADH-dependent reductase (NQO1) has been discovered
recently [28]. This reductase is a p53-binding partner, and,
upon reactive oxygen species generation in cells, p53 is
released from NQO1, which then induces apoptosis. We
sought to determine whether CBR1, another nicotinamide-
dependent reductase, could act similarly as part of a p53
complex by measuring p53 levels following serum-with-
drawal-induced apoptosis. These studies revealed no ubiq-
uitination nor a decrease in p53 concentration following
CBR1 inhibition as when NQO1 inhibitors are added to cells,
suggesting that CBR1’s involvement with the apoptotic
machinery does not follow the pattern established for other
oxidoreductases (data not shown).
Discussion
We have explored a conceptually new approach for the
discovery of novel potent and selective inhibitors of cellular
proteins. Rather than attempt to search extensively through
chemical space using large chemical libraries, we greatly
expanded the amount of biological target space sampled in a
single screen with only a limited collection (107) of small
drug-like molecules of limited chemical diversity. The
morphology-based screen led to the identiﬁcation of
hydroxy-PP, which exhibited a multi-dimensional morpho-
logical signature distinct from a known kinase inhibitor of
related structure (PP2). Not surprisingly, hydroxy-PP in-
hibited protein kinases based on its similarity in structure to
the known Src-family kinase inhibitor PP2. In order to
discover the new target of hydroxy-PP, an afﬁnity-based
screen was carried out. This approach revealed a new protein
target for hydroxy-PP that was not inhibited by PP2. The
target identiﬁed for hydroxy-PP and validated by X-ray
crystallography was not a protein kinase, but the NADPH-
dependent oxidoreductase, CBR1.
The surprising ability of a protein kinase inhibitor to cross-
inhibit a member of a completely distinct protein family by
simple hydroxyl-group substitution was rationalized based on
X-ray structure analysis of the hydroxy-PP-binding site of
CBR1. The protein kinase pocket occupied by PP in Hck is
closely related, in terms of overall shape, to the hydroxy-PP-
binding site of CBR1. Moreover, the hydroxyl group on
hydroxy-PP makes contact with two catalytically essential
residues in CBR1, thus providing direct structural insight into
the original structure–activity relationships identiﬁed by
morphology-based screening.
Genetic models have conﬁrmed the importance of CBR1 in
producing cardiac myocyte–toxic metabolites of important
anthracyclines, such as daunorubicinol [29]. The discovery of
a small-molecule inhibitor of CBR1 and the evidence of
improved cell killing by daunorubicin in conjunction with
hydroxy-PP-Me of lung adenocarcinoma cells now allows for
assessment of this potential improvement to current adjuvant
therapy for treating breast cancer and childhood leukemias
by reducing or preventing the cardiotoxicity currently
associated with anthracycline therapy. Further studies in
mice treated with daunorubicin and hydroxy-PP-Me are
being initiated to investigate possible cardiotoxicity reduc-
tion once the in vivo organ distribution and pharmacoki-
netics of hydroxy-PP-Me are determined. In particular,
distribution of hydroxy-PP-Me in the heart may be essential
to block daunorubicin-induced cardiotoxicity because it is
thought that CBR1 activity in the heart is responsible for
producing the high local concentration of daunorubicinol
that is toxic to cardiomyocytes.
The discovery of a potent and selective CBR1 inhibitor also
provides a powerful tool for discovery of pathways in which
CBR1 plays a role. The CBR1 knockout is lethal, preventing
such studies by genetic means. In a limited screen conducted
so far, one process found to be most sensitive to CBR1
inhibition was serum-withdrawal-induced apoptosis. The
selective CBR1 inhibitor hydroxy-PP-Me was able to block
more than 90% of apoptosis induced by this stimulus. This
pathway was not known to be dependent on the oxidor-
eductase CBR1, thus validating that the compounds discov-
ered in such screens can lead to chemical tools capable of
uncovering novel functions of key signaling regulators.
The apparent paradox that CBR1 serves a pro-apoptotic
function during serum-withdrawal-induced apoptosis but has
ap r o t e c t i v ef u n c t i o nw h e nc e l l sa r ec h a l l e n g e dw i t h
anthracyclines is a consequence of the different roles of the
natural and unnatural (anthracycline) substrates of CBR1.
The means by which inhibition of CBR1 causes increased cell
death in anthracycline-challenged cells is through blocking
the anthracycline-detoxiﬁcation activity of CBR1. However,
the anti-apoptotic effect of blocking CBR1 activity during
serum-withdrawal-induced apoptosis is unclear. Inhibition of
CBR1 may prevent generation of H2O2 via cellular quinone
reduction by CBR1 and the subsequent comproportionation
reaction of a cellular hydroquinone species and O2 to form
H2O2 [30]. Further experiments to determine the cellular
substrates of CBR1 that are involved in execution of serum-
withdrawal-induced apoptosis using methods for directly
radiolabeling reduction products are being pursued [31].
The present study suggests that current focused collections
of small molecules for cell-based screens contain potent
ligands for cellular targets that might be missed when screens
based on single readouts or single-cell processes are used.
Efforts to include more speciﬁc readouts in the microscopy-
based screens, such as use of phospho-speciﬁc antibodies for
reading out speciﬁc kinase activation, have been recently
described [1]. Other ﬂuorescent readouts, including tagged
fusion proteins for visualization of individual protein
trafﬁcking events and ﬂuorescent sensors of metals such as
Ca
2þand Zn
2þ, and other visualization methods may increase
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novel small molecules.
Materials and Methods
Cell culture and cell plating. SKOV3 (ovarian epithelial cancer),
A549 (lung epithelial cancer), and SF268 (central nervous system
epithelial cancer) were chosen for their broad genetic diversity and
obtained from the National Institutes of Health. These human cells
were grown and maintained in RMPI medium (Mediatech, Herndon,
Virginia, United States) with 5% fetal calf serum (FBS, HyClone,
Logan, Utah, United States). DU145 (prostate epithelial cancer) cells
(ATTC, Manassas, Virginia, United States) were maintained in MEM
with 5% FBS. HUVEC cells (VEC Technologies, Rensselaer, New York,
United States) were maintained in MCDB131 medium (VEC
Technologies) with 10% FBS. For the assays 1,000–1,800 trypsinized
(Mediatech) cells per well (depending on cell type) were plated in 384-
well plates (Corning Costar, Acton, Massachusetts, United States)
using a Multidrop (Thermo Labsystems, Beverly, Massachusetts,
United States) and incubated for 24 h, the approximate doubling
time. Six cell plates were made for each cell line.
Compounds. Compound stocks were maintained in DMSO.
Compound information was stored in ActivityBase (ID Business
Solutions, Guildford, United Kingdom). Compounds were serially
diluted in 384-well drug plates to achieve eight concentrations
diluting 33 in DMSO between wells using a Multimek (Beckman
Coulter, Fullerton, California, United States). Wells were reserved on
every drug plate for negative and positive controls. Negative-control
wells contained DMSO only and the positive-control wells received a
titration of paclitaxel, a tubulin stabilizer (Sigma-Aldrich-Fluka, St.
Louis, Missouri, United States). For known kinase inhibitors for which
we possessed information about the IC50 against known targets, the
starting concentration was customized such that the IC50 would be in
the middle of the dose-response (eight 3-fold dilutions) curve. Small
molecules were tested at 40 lM on cells based on the logic that
cellular effects on cells at greater than 100 lM concentration are
most likely nonspeciﬁc and that we would most likely get a full-dose
response after eight 3-fold dilutions (6 nM to 40 lM ﬁnal
concentrations).
Compound addition. Compounds were added to cell plates from
drug plates. Compound mixed with medium was added to the cells to
achieve a 0.4% DMSO concentration on prepared cell plates using a
PlateTrak (CCS Packard, Torrance, California, United States). Treated
cells were incubated for another 24 h, the compound exposure time.
Staining. Cells were stained for visualization of the nuclei, Golgi
apparatus, and microtubules. Cells were ﬁxed with 4% formaldehyde
(Polysciences, Warrington, Pennsylvania, United States) for 1 h;
washed in TBS (Teknova, Half Moon Bay, California, United States);
blocked in 0.01% Triton X-100 (ICN Biomedicals, Irvine, California,
United States) and 1% BSA in TBS (Teknova) and then left to
incubate for 1 h; stained with 0.01% Triton X-100, 0.1% BSA, 5 lg/ml
Hoechst 33342 (Molecular Probes, Eugene, Oregon, United States),
5 lg/ml FITC-Lectin Lens Culinaris (Sigma-Aldrich-Fluka), and 3 lg/
ml Rhodamine Red–labeled monoclonal antibody DM1a (courtesy of
Tim Stearns) for 1 h; and then washed in TBS. All of these steps were
performed with a PlateTrak using an ELx405 microplate washer (Bio-
Tek Instruments, Winooski, Vermont, United States). This was done
in triplicate for each cell line.
Imaging. Cells were imaged on an inverted Axiovert 100M
epiﬂuorescent microscope (Carl Zeiss, Oberkochen, Germany) with
a5 3 objective and a Xenon lamp (Sutter Instruments, Novato,
California, United States). A 53 magniﬁcation was chosen (rather
than 403) primarily as a function of the need to acquire a large
number of individual cells in order to gather statistically relevant
data on relatively rare subpopulations. The number of cells in a
randomly acquired 403 image is not sufﬁcient to make meaningful
statistical measurements across many cells. Metamorph (Universal
Imaging, Downingtown, Pennsylvania, United States) was used to
control the motorized x, y, z stage (Prior Scientiﬁc, Rockland,
Massachusetts, United States) that moved the plate to each well,
autofocused, and took three successive ﬂuorescent images with an
Orca 100 camera (Hamamatsu, Hamamatsu City, Japan). Exposure
times were set to minimize the number of saturated pixels in the
image. Images of the negative-control wells typically contained 800 to
1,200 cells, depending on the cell line.
Image analysis. Custom software was used to segment objects and
extract attributes. Segmentation of nuclei used a gradient method for
edge detection, the microtubules were segmented using watershed,
and the Golgi apparatus was segmented by expanding the mask from
the nuclei. Object attributes are listed in Table S1.
Object classiﬁcation. Two algorithms using object attributes from
the nuclei classify objects into different phases of the cell cycle. The
cell-cycle algorithm classiﬁes each cell by total intensity of its nuclei
(DNA content) as Gap 1, Synthesis, or Gap 2. The condensation
algorithm classiﬁes each cell as condensed or not condensed using the
mean intensity and area of the nuclei. Nuclei condensation is a
surrogate marker for mitosis; meaning that condensed cells are
typically mitotic cells but may be rounded-up cells.
Data storage and analysis. Custom software was written to
automatically identify, register, organize, and analyze the images.
Results from image analysis were automatically stored in an Oracle
(Redwood Shores, California, United States) database. Information
about the experimental conditions was manually entered into the
database. Finally, software was written to compile compound
information from ActivityBase, experiment design, image analysis,
and data analysis into one report. SpotFire DecisionSite (Somerville,
Massachusetts, United States) was used to visualize the attribute and
PCA data.
Quality control. Quality metrics computed on the negative- and
positive-control wells were used to determine the overall quality of
the plate. Poor-quality plates were discarded and new plates were
made. Image statistics—background, contrast, and saturation–were
measured, and poor quality images were discarded. Results were
aggregated over good images from replicated cell plates.
Chemicals and chemical synthesis. Reactigel 6X was purchased
fromPierceBiotechnology(Rockford,Illinois,UnitedStates).NADPH,
glutathione, menadione, and daunorubicin were purchased from
Sigma. AlamarBlue was purchased from Biosource (Camarillo, Cali-
fornia, United States) International. Boronic acids were purchased
from Combi-Blocks (San Diego, California, United States), and palla-
dium complexes were purchased from Strem Chemical (Newburyport,
Massachusetts, United States). Other starting materials and synthetic
reagents were purchased from Aldrich unless otherwise noted.
4-Amino-1-tert-butyl-3-phenylpyrazolo[3,4-d] pyrimidines (PP2 and
hydroxy-PP) were synthesized according to Hanefeld et al.[32]. Benzyl
bromide was used to protect the hydroxyl group for the hydroxy-PP
synthesis. Hydrogenation (10% palladium on carbon) resulted in
benzyl deprotection to yield hydroxy-PP.
Hydroxy-PP: Colorless powder;
1H NMR (400 MHz, DMSO-d6) d
9.69 (brs), 8.22 (1H, s), 7.33 (1H, dd, J = 7.5, 7.5 Hz), 7.05 (2H, m), 6.86
(1H, dd, J = 7.5, 2 Hz), 5.74 (s), 1.73 (9H, s).
13C NMR (100 MHz,
DMSO-d6) d 158.1 (s), 157.8 (s), 154.6 (d), 153.8 (s), 141.7 (s), 134.5 (s),
130.2 (d), 118.9 (d), 115.6 (d), 115.0 (d), 98.5 (s), 59.6 (s), 28.7 (q). HR-
EIMS calculated for C15H17N5O 283.1433 found 283.1434.
Chemical probes with a linker (PP-L and hydroxy-PP-L) were
synthesized by the coupling reaction of the corresponding pyrazo-
lo[3,4-d] pyrimidines with 1-bromo-11-tert-butoxycarbamoyl-3,6,9-
trioxaundecane by treatment with sodium hydride.
Hydroxy-PP-Me was synthesized in three steps from 4-chloro-5-
iodo-7H-pyrrolo[2,3-d]pyrimidine (compound 1 in Figure S4), with a
50% overall yield. Compound 1 was synthesized as previously
described [33]. Mitsunobu alkylation of compound 1 proceeded
efﬁciently to yield the N-alkylated pyrrolopyrimidine (compound 2 in
Figure S4). SNaryl reaction of this product with methylamine in THF
provided compound 3 (Figure S4), which was subsequently coupled to
meta-hydroxyphenylboronic acid under Suzuki conditions to afford
hydroxy-PP-Me.
To produce 4-chloro-7,7a-dihydro-5-iodo-7-isopropyl-4aH-pyrro-
lo[2,3-d]pyrimidine (compound 2 in Figure S4), the following steps
were taken. To a dry 50-ml round-bottom ﬂask was added 4-chloro-5-
iodo-7H-pyrrolo[2,3-d]pyrimidine prepared as previously described
[33] (0.5 g, 1.78 mmol) and PPh3 (0.84 g, 3.2 mmol). The materials were
dried under high vacuum for 20 min, and the ﬂask was purged with
argon. THF (30 ml) and isopropanol (0.3 ml, 3.9 mmol) were added
and the ﬂask was cooled in an ethylene glycol/dry-ice bath, and
diisopropyl azodicarboxylate (0.47 g, 2.3 mmol) was added drop by
drop to the stirred solution. After 18 h, the volatiles were evaporated
in vacuo and the resultant oil was dissolved in ethyl acetate (50 ml)
and 50% saturated sodium bicarbonate (50 ml). The organics were
extracted with ethyl acetate (3 3 50 ml), dried with sodium sulfate,
a n de v a p o r a t e di nv a c u ot oy i e l da no r a n g eo i l .S i l i c ag e l
chromatography (ethyl acetate:hexanes) afforded the desired product
as a yellow solid (480 mg, 84% yield).
1H NMR (399.6 MHz, CDCl3) d
1.5 (6H, d, J = 6.4 Hz), 5.1 (1H, sp, J = 6.8 Hz), 7.4 (1H, s), 8.6 (1H, s).
To produce 7,7a-Dihydro-5-iodo-7-isopropyl-N-methyl-4aH-
pyrrolo[2,3-d]pyrimidin-4-amine (compound 3 in Figure S4), 4-
Chloro-7,7a-dihydro-5-iodo-7-isopropyl-4aH-pyrrolo[2,3-d]pyrimi-
dine (0.3 g, 0.93 mmol) from above was placed within a 15-ml pressure
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was left to stir overnight. The volatiles were removed in vacuo, and the
residue was dissolved in methanol; then 5 ml of silica gel was added,
and the volatiles were removed in vacuo. The adhered product was
puriﬁed by silica gel chromatography (ethyl acetate:hexanes), and the
requisite fractions were pooled and evaporated in vacuo to yield the
desired product (0.25g, 85% yield).
1H NMR(399.6 MHz, CDCl3) d 1.43
(6H, d, J = 6.8 Hz), 3.13 (3H, d, J = 4.8 Hz), 5.0 (1H, sp, J = 6.8 Hz),
7.02 (1H, s), 8.35 (1H, s).
To produce hydroxy-PP-Me, 7,7a-Dihydro-5-iodo-7-isopropyl-N-
methyl-4aH-pyrrolo[2,3-d]pyrimidin-4-amine (0.15 g, 0.475 mmol)
from above was placed in a 50-ml round-bottom ﬂask in which
12 ml of dimethoxy ethylene glycol was added. 3-Hydroxyphenylbor-
onic acid (0.262 g, 1.9 mmol, predissolved in 3.3 ml of ethanol) was
added at once and was followed by 1.9 ml of saturated aqueous
sodium carbonate. Pd
0(PPh3)4 (55 mg, 47 lmol) was added to the
reaction; the vessel was purged with argon and set to stir at 80 8C for
48 h. The reaction was subsequently cooled and ﬁltered through a bed
of diatomatious earth (Celite, Sigma-Aldrich). The ﬁltrate was
evaporated in vacuo, and the residual material was adhered to silica
gel using ethyl acetate as a solvent. Silica gel chromatography (ethyl
acetate:hexanes) and evaporation in vacuo of the requisite fractions
yieldedthedesiredproduct(94.8mg,70.7%yield).
1HNMR(399.6MHz,
d
6-DMSO)d1.76(6H,d,J=6.8Hz),5.03(3H,d,J=4.8Hz),5.34(1H,sp,
J = 6.4Hz), 5.53 (1H,q,J = 4.8 Hz),6.73 (1H,m), 6.85 (1H,m), 7.25 (1H,
app t, J = 7.6 Hz), 7.37 (1H, s), 7.59 (1H, s).
Cell lines. A549 cells were purchased from ATCC and cultured in
the F-12K medium with 10% of FBS. Cells were maintained at 37 8C
in an atmosphere of 5% CO2. Adherant cells were released for
passaging using an isotonic Trypsin solution (0.25% Trypsin, 0.02%
Versene). Rabbit anti-human CBR1 antibody was obtained from Dr.
Tsuchida [34]. The CBR expression vector, pET-11aCR, was obtained
from Dr. Wermuth [35].
Preparation of cell extracts. Cells were collected and washed with
PBS buffer once then sonicated in buffer A containing 50 mM Tris-
HCl (pH 7.4), 2 mM dithiothreitol, 5 mM EDTA, 5 mM EGTA, 20 mM
MgCl2, and 1 ll/ml protease inhibitor cocktail Set III (Calbiochem,
San Diego, California, United States). The solution was centrifuged
for 15 min at 10,000 g and 4 8C. The supernatant was recovered and
loaded on the afﬁnity matrices or stored at –80 8C.
Preparation and use of afﬁnity reagents. Pyrazolopyrimidines were
coupled to Reactigel 6X beads at a calculated ﬁnal concentration of
10–50 lmol/ml of resin. They were stored at 4 8C as a 50% (v/v) slurry
in ethanol. 20 ll of the suspension was washed with 1 ml of buffer A
with 200 mM NaCl and 0.1% IGEPAL CA-630 (Sigma), then the cell
supernatant (1–2 mg protein) was added. After 1 h incubation at 4 8C,
the beads were washed with the same buffer followed by addition of
40 llo f1 3 Laemmli sample buffer.
Electrophoresis. Proteins bound to the afﬁnity matrix were
recovered with 13 Laemmli sample buffer. Following heat denatura-
tion for 3 min, the bound proteins were separated by 12% SDS-PAGE
followed by immunoblotting analysis or silver staining. Silver staining
was performed with the following parameters: ﬁxative, 250 ml of 50%
methanol; rinse, MilliQ puriﬁed water (Millipore, Billerica, Massa-
chusetts, United States) containing 10 lM DTT, followed by 0.1%
AgNO3 in MilliQ water (w/v); developer, 15 g of Na2CO3 in 500 ml of
MilliQ water containing 250 ll of 37% formaldehyde.
Protein identiﬁcation: Materials. Siliconized 0.65-ml tubes from
PGC Scientiﬁcs (Frederick, Maryland, United States) were washed
with methanol and water prior to use. Reverse-phase packing
material was from Phenomenex (Torrance, California, United States);
fused-silica capillary tubing was purchased from Dionex (Sunnyvale,
California, United States). The matrix solution used for MALDI
experiments containing aCHCA (a-cyano-4-hydroxycinnamic acid)
was from Agilent Technologies (Palo Alto, California, United States).
Solvents were purchased from Fisher Chemicals (Tustin, California,
United States); all other reagents were obtained from Sigma-Aldrich-
Fluka.
Enzymatic digestions. The gel bands were cut in a laminar ﬂow
hood under conditions to minimize contamination. Sample reduc-
tion, alkylation, and digestion was carried out a using Genomic
Solutions Proprep digestion robot (Genomic Solutions, Ann Arbor,
Michigan, United States). The in-gel digestions were performed
according to a modiﬁed in-house protocol, under laminar ﬂow.
Reduction with 10 mM DTT was allowed to proceed for 20 min at
50 8C. Iodoacetamide was dissolved in 20 mM NH4HCO3 (pH 8.2) with
10% ACN, and alkylation of cysteine residues was carried out for 1 h
at room temperature. Tryptic digestion was initiated by the addition
of 1% (w/w) of side-chain-modiﬁed, TPCK-treated porcine trypsin
and was allowed to proceed at 37 8C for 4 h. The digests were
extracted manually with 40 ll of ammonium bicarbonate buffer
solution followed by two 30-ll extractions with 60% acetonitrile. The
digest extracts were pooled and concentrated to approximately 30 ll,
and 10 ll of each mixture was desalted using C18 Zip Tips (Millipore).
The samples were eluted into 10 ll (60% ACN, 0.2% TFA), and the
volume was reduced to 3 ll using vacuum centrifugation. Targets for
MALDI were spotted using the dried-droplet method by adding 0.7 ll
of the sample and 1.0 llo fa,CHCA matrix solution. For ESI
experiments, the remaining sample (approximately 2 ll) was injected
onto a nano-capillary C18 column for HPLC separation.
MALDI-TOF/TOF-MS analysis. MALDI-MS data were acquired in
an automated mode using a 4700 Proteomics Analyzer (Applied
Biosystems, Foster City, California, United States). This instrument
employed a neodymium:yttrium aluminum garnet frequency-tripled
laser operating at a wavelength of 354 nm and a laser repetition rate
of 200 Hz. Initially, a MALDI-MS spectrum was acquired from each
spot (1,000 shots/spectrum). Then peaks with a signal to noise ratio
greater than 15 in each spectrum were automatically selected for
MALDI-CID-MS analysis (7500 shots/spectrum). A collision energy of
1 keV was used with air as the collision gas for collision-induced
dissociation (CID) accumulation. After acquisition, the data were
subjected to automatic baseline correction, mathematically
smoothed, and stored in an Oracle database. Assuming that all ions
were singly charged, peak lists from all MS/MS spectra were
automatically extracted from the Oracle database and submitted
for batch-analysis database searching using an in-house copy of
Protein Prospector (version 4.3) with the new program LCBatch-Tag
or an in-house copy of Mascot, version 1.8 (Matrix Science, Boston,
Massachusetts, United States). The latter was managed using the
Mascot Daemon (Matrix Science, Boston, Massachusetts, United
States) program running on the same computer. The MS/MS mass
values submitted to both search engines were limited using the
following criteria: minimum S/N threshold was 8–10, masses of 0–60
Da and within 20 Da of the precursor were excluded, and a maximum
of 60 peaks per spectrum were submitted.
Protein Prospector searches were performed by specifying the
inclusion of high-energy fragment ions characteristic of the TOF/
TOF instrument, whereas Mascot searches included only the low-
energy fragment ions and internal ions. For externally calibrated
spectra, the allowed mass tolerance that was speciﬁed between
expected and observed masses for searches was 675 ppm for MS
data, 6200 ppm for MS/MS parent ions, and 6250 ppm for MS/MS
fragment ions. All samples were searched against the nonredundant
National Center for Biotechnology Information database
(NCBInr.02.25.2002).
nLC-ESI-Qq-TOF MS analysis. Tryptic peptides were subject to
LC-MS/MS analysis on a QSTAR Pulsar mass spectrometer (MDS
Sciex, Concord, Ontario, Canada) operating in positive-ion mode.
Chromatographic separation of peptides was performed as de-
scribed earlier except that formic acid was used as the ion-pairing
agent. The LC eluent was directed to a micro-ionspray source.
Throughout the running of the LC gradient, MS and MS/MS data
were recorded continuously based on a 5-s cycle time. Within each
cycle, MS data were accumulated for 1 s, followed by CID
acquisitions of 4 s on ions selected by preset selection parameters
of the information-dependent acquisition (IDA) method. In general
the ions selected for CID were the most abundant in the MS
spectrum, except that singly charged ions were excluded and
dynamic exclusion was employed to prevent repetitive selection of
the same ions within a preset time. Collision energies were
programmed to be adjusted automatically according to the charge
state and mass value of the precursor ions. Peak lists for database
searching were created using a script from within the Analyst
software. Searches were performed using the two search engines
meantioned earlier except that only the low-energy CID fragments
characteristic of the ESI-Qq-TOF instrument were considered. The
allowed mass-tolerance range between expected and observed
masses for searches was 6100 ppm for MS peaks and 60.1 Da for
MS/MS fragment ions.
Expression and puriﬁcation of recombinant CBR1. Isopropyl-b-D-
thiogalactoside (ﬁnal: 1 mM) was added to cultures of E. coli
BL21(DE3) harboring pET-11aCR vectors when absorption at 600
nm of the culture became 0.6–0.7 AU. The cells were centrifuged after
induction for 4–6 h, then the pellet was suspended in the buffer A
and sonicated. The solution was centrifuged for 15 min at 10,000 g
and 4 8C. The supernatant was loaded on Glutathione Sepharose 4B
beads (Amersham Pharmacia Biotech, Little Chalfont, United King-
dom). Beads were washed four times with buffer A. Bead-binding
proteins were eluted with 50 mM sodium phosphate (pH 6.1)
containing 500 mM NaCl and 20 mM glutathione. The eluate was
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exchange the buffer to 10 mM Tris-HCl (pH 7.4).
CBR1 assay. CBR1 activity was determined spectrophotometrically
at 25 8C. The standard assay mixture consisted of 50 mM sodium
phosphate (pH 6.8), 200 lM NADPH, and 200 lM menadione in a
total volume of 1 ml. Compounds were dissolved in DMSO as 1003
stock solutions. Reactions were initiated by the addition of enzyme,
and initial rates were determined by monitoring the disappearance of
NADPH at 340 nM. Controls without substrates or enzyme were
routinely included.
Kinase assays. Fyn and p38 kinases were expressed in bacteria and
puriﬁed as previously described [13,37]. Protein kinase A and Protein
kinase B were obtained commercially (Upstate Cell Signaling
Specialties Charlottesville, Virginia, United States). For the inhibition
assay, various concentrations of inhibitor were incubated with 50 mM
Tris (pH 8.0), 10 mM MgCl2, 1.6 mM glutathione, 1 mg/ml BSA, 0.1 mg/
ml of the requisite substrate peptide (see Figure S1), 3.3% DMSO, 11
nM (2 lCi) [c-
32P]ATP (6,000 Ci/mmol, NEN), and kinase in a total
volume of 30 ll for 30 min. Reaction mixtures (27 ll) were spotted
onto a phosphocellulose disk and washed with 0.5% H3PO4. The
transfer of
32P was measured by standard scintillation counting. The
IC50 values were deﬁned to be the concentration of inhibitor at which
the counts per minute was 50% of the control disk. When the IC50
value fell between two measured concentrations, it was calculated
based on the assumption of an inversely proportional relationship
between inhibitor concentration and counts per minute between the
two data points.
Cell viability assay and PI-stained cell assay. Cell viability was
determined by the alamarBlue reagent reduction assay in a 96-well
culture plate, measuring the absorbance at 570 and 600 nm
spectrophotometrically. The amount of PI-stained cells was estimated
by measuring ﬂuorescence following incubation with PI (5 lg/ml). For
both experiments, data are shown as the percentages of nontreated
control cells.
p53 and ubiquitination detection in A549 cells. A549 cells
maintained as described earlier were seeded in 6-cm dishes at a
density of 1.8310
4 cells/cm
2 and incubated in the presence of 3 ml of
F-12K and 10% FBS. After 48 h, the medium was replaced with 3 ml
of serum-free F-12K containing either PP2, hydroxy-PP, or hydroxy-
PP-Me (prepared from 5 mM DMSO stock solutions), each at
concentrations of 2, 5, or 10 lM. Experiments were routinely
performed in duplicate, and controls with representative DMSO
concentrations were included. After 48 h incubation, the medium was
removed, and the cells were lysed with 0.5 ml of modiﬁed RIPA buffer
(1% NP-40, 50 mM Tris, 150 mM NaCl, 2 mM EDTA, 2 mM Na3VO4,
0.1% SDS, 0.1 mM DTT, and one Complete Mini, EDTA-free protease
inhibitor tablet [Roche, Basel, Switzerland] per 10 ml) for 10 min. The
contents of each plate were transferred to 1.5-ml micro-centrifuge
tubes, the tubes were sonicated in a bath sonicator for 5 min, and the
lysates were cleared by centrifugation (14,000 g, 10 min). The
supernatant was collected, and the protein concentration was assayed
using the Bio-Rad DC protein assay (Bio-Rad, Hercules, California,
United States). Equal quantities of protein boiled for 1 min in 13
Lamelli buffer were subjected to electrophoresis using 7.5%
acrylamide Tris-Cl Criterion gels (Bio-Rad). Proteins were electro-
phoretically transferred to nitrocellulose and immunoblotted with
DO-1 anti-p53 HRP conjugated antibody or the anti-ubiquitin
antibody Ub followed by anti-mouse IgG conjugated HRP (Santa
Cruz Biotechnology, Santa Cruz, California, United States). Immuno-
reactive proteins were analyzed by enhanced chemiluminescence
(Pierce Biotechnology).
Protein crystallization. The CBR1 was expressed in E. coli and
puriﬁed as described earlier. CBR1 (18 mg ml
 1) in 30 mM sodium
phosphate (pH 6.5), 100 mM KCl, and 20 lM DTT was incubated for
30 min with hydroxy-PP (1 mM ﬁnal concentration) prior to
crystallization. Within 2 d at room temperature, good diffracting
crystals of the orthorhombic space group P212121 were obtained by
vapor diffusion from 100 mM 2-(N-ethylmorpholino)ethanesulfonate
(pH 6.5), 2.0 M ammonium sulfate, and 5% PEG 400.
Data collection and structure determination. Orthorhombic
crystals of CBR1–hydroxy-PP diffracted to 1.1 A ˚ . A full dataset was
collected at the Advanced Light Source (Berkeley, California, United
States) beamline 8.3.1 with an ADSC Quantum 4 CCD detector. The
dataset was integrated and merged using the HKL2000 and
SCALEPACK programs (HKL Research, Charlottesville, Virginia,
United States) [37]. The structure was solved by molecular replace-
ment with AMoRe [18] using a modiﬁed porcine carbonyl reductase
model (1N5D). Crystallographic reﬁnement to 1.2 A ˚ was carried out
and electron density maps were produced using SHELXL [20]. Model
building was done using O [38] and Quanta 2000 (Molecular
Simulations, San Diego, California, United States). Detailed data
and reﬁnement statistics are listed in Table S5.
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Table S3. Inhibition Values of PP, Hydroxy-PP, PP2, and Hydroxy-PP-
Me against Four Protein Kinases
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Accession Numbers
The SwissProt (http://www.ebi.ac.uk/swissprot/) accession numbers for
CBR1 and NQO1 are P16152 and P15559, respectively. The ProSite
(http://au.expasy.org/prosite/) accession number for human CBR1 is
PS00061. The Protein Data Bank (http://www.rcsb.org/pdb/) accession
numbers for the other gene products discussed in this paper are
porcine carbonyl reductase (PDB 1N5D), Hck (PDB 1QCF), and short-
chain dehydrogenase substrate complexes (PDB 2AE2, 1FDS, and
1HZJ). The accession number for the crystal structure of the modiﬁed
human carbonyl reductase model reﬁned with SHELXL to 1.24 A ˚
with a crystallographic R-factor of 10.3% and a free R-factor of
13.4% is PDB 1WMA.
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